- Our commitment to new medicines
At ViiV Healthcare we are committed to delivering new HIV medicines that meet the changing needs of people living with HIV/AIDS. Through medicines with improved tolerability, safety, adherence and resistance profiles, we aim to improve clinical outcomes and quality of life for HIV-positive people.
The core of this commitment is the Research Alliance Agreement that ViiV Healthcare has signed with both GSK and Pfizer. Once a drug from these groups has been shown to demonstrate ‘proof of concept’ ViiV Healthcare has first refusal to take ownership of the molecule and advance it to later-stage clinical trials.
In addition to our own pipeline, we are seeking to in-partner patent protected competitive compounds (discovery stage through to marketed products) and technologies that will have a positive impact on the lives of patients living with HIV/AIDS. We are especially interested in clinical stage assets that have the potential to deliver a significantly differentiated product profile versus currently marketed HIV therapies.
We will consider various business arrangements including option based collaborations, standard licensing agreements, company acquisitions and promotions/co-promotions.
For further information please contact:
Dr. Trevor Scott
Vice President and Head, Business Development and Alliances
5 Moore Drive, Research Triangle Park, North Carolina 27709-3398, USA.
Tel. +1 919 483-8215
Fax + 1 919 315-0027